市場調查報告書
商品編碼
1494869
到 2030 年造影數位乳房X光攝影(CEDM) 市場預測:按影像類型、技術、應用、最終用戶和地區進行的全球分析Contrast Enhanced Digital Mammography (CEDM) Market Forecasts to 2030 - Global Analysis By Image Type (3D images and 2D images), Technology (Temporal Subtraction, Dual Energy CEDM and Other Technologies), Application, End User and By Geography |
根據 Stratistics MRC 的數據,2024 年全球造影數位乳房X光攝影(CEDM) 市場規模將達到4.6259 億美元,預計在預測期內將以12.8% 的年複合成長率成長,到2030 年達到9.5291 億美元。
造影數位乳房X光攝影(CEDM)是一種用於乳癌篩檢和診斷的先進影像技術。顯影劑注射到患者的血液中,以突出顯示乳房病變中的異常血管。這增加了乳房X光攝影中可疑區域的可見度,特別是在傳統乳房X光攝影無法得出結論的情況下。 CEDM結合了乳房X光攝影和顯影劑增強影像的優點,以提高乳癌檢測靈敏度,特別是當乳房組織緻密時。
根據美國乳癌統計數據,美國八分之一的女性(約 12.4%)在一生中會罹患侵襲性乳癌。根據世界衛生組織 (WHO) 的數據,乳癌是女性最常見的癌症,約佔亞洲女性癌症的 35%。
省時高效率的流程
數位乳房X光攝影以其快速結果而聞名,您的醫生可以立即看到結果。無需像傳統工藝那樣花費時間沖洗膠片。測試過程中,技術人員可以在電腦螢幕上查看結果。也可以放大或聚焦於特定位置。也可以修改對比度以區分正常和患病的乳房組織。因此,這已成為市場擴張的主要驅動力。
空間解析度降低
數位乳房X光攝影還具有降低空間解析度的能力。透過數位幾何放大,投影的鈣化影像超出了最低解析度限制。還有一個問題是顯示器上的影像放大能力無法替代真正的、更集中的幾何放大。結果,這阻礙了市場的擴張。
新技術的出現
由於 CEDM 的技術進步以及政府宣傳活動的多項意識提升活動,預計乳癌死亡率將會下降。然而,對於厚乳房,引入造影數位乳房X光攝影將增強癌症診斷。全球乳癌篩檢計畫的推出和乳癌發生率的上升正在推動市場擴張。
高成本
數位乳房攝影的價格高於使用傳統底片的價格。據認為,這筆費用將透過設備改進而減少的拍攝時間來彌補。然而,研究尚未證明檢測乳癌有任何益處。此外,與傳統的乳房X光攝影相比,顯影劑過敏反應的幾率較低,輻射劑量較高。造影乳房X光攝影解決方案正在阻礙市場成長,因為乳房 MR 更耗時、更昂貴,而且會讓患者感到不舒服。
市場受到 COVID-19 大流行的負面影響。全球大流行大大減少了乳癌篩檢、癌症管理就診和癌症手術。由於多個國家採取封鎖措施,以及包括乳房X光攝影X 光攝影系統在內的各種 X 光成像設備的製造和生產延遲,疫情的爆發影響了乳房X光攝影光攝影系統業務的成長。
診斷預計將成為預測期內最大的細分市場
由於影像技術的進步以及對乳癌早期檢測的日益重視,造影數乳房X光攝影(CEDM)市場的診斷部分正在經歷顯著成長。與傳統的乳房X光攝影相比,CEDM由於其增強的對比度和改進的病變檢測能力而擴大在診斷程序中被採用。人們越來越認知到早期診斷的重要性以及對更準確成像方式的需求也推動了對 CEDM 系統的需求。隨著患者數量的增加以及醫療保健提供者優先考慮高效的診斷工具,CEDM 市場的診斷領域預計將持續成長。
醫院產業預計在預測期內年複合成長率最高
近年來,醫院領域的造影數位乳房X光攝影(CEDM)市場經歷了顯著成長。由於技術的進步和人們對早期乳癌檢測重要性的認知不斷提高,醫院擴大實施 CEDM 系統。此外,CEDM 與醫院環境的整合使患者能夠在同一屋簷下獲得全面的乳房攝影服務,從而促進了這一領域的成長。旨在改善乳癌篩檢的有利報銷政策和政府措施進一步支持醫院採用 CEDM。
在預測期內,由於乳癌發生率高且不斷增加,預計北美將佔據最大的市場佔有率。預計推動市場成長的關鍵因素包括該地區擴大採用先進的診斷技術來檢測乳房惡性、造影增強數位乳房X光攝影(CEDM)相對於傳統MRI技術的優越性、乳癌發病率以及早期檢測和預防意識的篩檢。
由於私人和政府機構為提供更好的醫療設施所做的各種努力,預計亞太地區在預測期內將呈現最高的年複合成長率。與標準 MRI 相比,造影數位乳房X光攝影(CEDM) 的成本更低,手術時間更短,且該地區乳癌患者數量迅速增加。提供免費癌症篩檢的政府計畫也推動了該產業的發展。
According to Stratistics MRC, the Global Contrast Enhanced Digital Mammography (CEDM) Market is accounted for $462.59 million in 2024 and is expected to reach $952.91 million by 2030 growing at a CAGR of 12.8% during the forecast period. Contrast-Enhanced Digital Mammography (CEDM) is an advanced imaging technique used in breast cancer screening and diagnosis. It involves the injection of a contrast agent into the patient's bloodstream, which highlights abnormal blood vessels in breast lesions. This enhances the visibility of suspicious areas on mammograms, particularly in cases where traditional mammography may be inconclusive. CEDM combines the benefits of digital mammography with contrast-enhanced imaging, offering improved sensitivity for detecting breast cancer, especially in dense breast tissue.
According to the U.S. Breast Cancer Statistics, about 1 in 8 women in the U.S. (about 12.4%) would develop invasive breast cancer over the course of her lifetime. Breast cancer, which makes up around 35% of all occurrences of female cancer in Asia, is the most frequent cancer among women, according to the World Health Organization.
Time efficient process
A digital mammography is renowned for its quick results, which are available right away for the doctors to review. There is no requirement to spend time on film developing as there would be in a conventional process. During the examination, the technician can see the results on the computer screen. They can also be altered to magnify and concentrate on specific locations. It is also feasible to alter the contrast to distinguish between normal and diseased breast tissues. As a result, this is the main element fueling the market's expansion.
Reduced spatial resolution
Digital mammography also has a function with a lower spatial resolution. The projected calcification images are elevated above the lowest resolution limit by the digital geometric magnification. The fact that the picture magnification power on the monitor is not a substitute for true geometric magnification with better focus is another problem. As a result, this factor is preventing the market from expanding.
Advent of new technology
The death rate from breast cancer is projected to decrease as a result of technological developments in CEDM and several government campaigns to raise awareness. In thick breasts, however, the introduction of contrast-enhanced digital mammography enhances cancer diagnosis. The introduction of breast cancer screening programmes worldwide and the rise in breast cancer prevalence have fuelled the market's expansion.
High cost
The price of a digital mammography is more than one using traditional film. The procedure's time savings would cover this cost for the improved facilities. However, research falls short of demonstrating the advantages of breast cancer detection. Additionally, there is a lower chance of a contrast allergic reaction and a higher radiation dose compared to traditional mammography. Contrast-enhanced mammography solutions are hindering the market's growth because breast MR is more time-consuming, expensive, and uncomfortable for patients.
The market has been adversely affected by the COVID-19 pandemic. Globally, the pandemic led to significant declines in breast cancer screening, cancer management visits, and cancer operations. Due to the lockdown measures in several nations and the delays in manufacturing and production of a wide variety of X-ray imaging devices, including mammography systems, the pandemic epidemic has had an impact on the growth of the business for mammography systems.
The diagnosis segment is expected to be the largest during the forecast period
The diagnosis segment in the Contrast Enhanced Digital Mammography (CEDM) market has witnessed notable growth due to advancements in imaging technology and an increasing emphasis on early detection of breast cancer. CEDM offers enhanced contrast and improved lesion detection capabilities compared to traditional mammography, driving its adoption in diagnostic procedures. Additionally, rising awareness about the importance of early diagnosis and the need for more accurate imaging modalities has spurred demand for CEDM systems. With a growing patient pool and healthcare providers prioritizing efficient diagnostic tools, the diagnosis segment in the CEDM market is poised for continued growth.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospital segment within the Contrast Enhanced Digital Mammography (CEDM) market has witnessed significant growth in recent years. With advancements in technology and increasing awareness about the importance of early detection of breast cancer, hospitals have been increasingly adopting CEDM systems. Additionally, the integration of CEDM into hospital settings provides patients with access to comprehensive breast imaging services under one roof, contributing to the segment's growth. Favourable reimbursement policies and government initiatives aimed at improving breast cancer screening have further propelled the adoption of CEDM in hospitals.
North America is projected to hold the largest market share during the forecast period owing to high prevalence and increase in incidence of breast cancer. Some of the key factors anticipated to propel the market growth include the rising adoption of advanced diagnostic techniques for breast malignancy detection in the region, the superiority of contrast-enhanced digital mammography over the traditional MRI technique, rising incidence of breast cancer, and growing awareness of early detection and screening of breast cancer.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to various initiatives taken by private and government institutions to provide better health care facilities. Low cost of contrast-enhanced digital mammography, quicker procedure time compared to standard MRI, and a sharp increase in the number of breast cancer patients in the area. Government programmes offering free cancer screenings are also propelling the industry.
Key players in the market
Some of the key players in Contrast Enhanced Digital Mammography (CEDM) market include Allengers Medical Systems Limited, Bmi Biomedical International S.R.L., Carestream Health, Gamma Medica, Inc., GE Healthcare, Hologic Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Metaltronica S.p.A, Planmed Oy, Siemens Healthcare GmbH, Toshiba Medical Systems and Villa Systems Medical SpA.
In May 2024, Konica Minolta, Inc. has been actively working to use recycled plastics, which contribute to a recycling-oriented society. Leveraging its know-how of high-functionality recycling, the Company has started supplying recycled plastics derived from used polycarbonate (PC) water bottles through joint development with NEC Platforms, Ltd. (NEC Platforms) for exterior parts of an Aterm home Wi-Fi router manufactured by NEC Platforms.
In November 2023, Toshiba Medical Systems Europe is launching a new 80-row multislice CT scanner, called Aquilion Prime SP, at next week's U.K. Radiological Congress (UKRC) in Manchester. Aquilion Prime SP includes a number of Toshiba technologies designed to meet increasing demands for superior imaging and outstanding economic performance, according to the company. It includes technologies such as Toshiba's PureVision Optics mode, which makes up to 40% more efficient use of x-rays.